ARGX 241220 210.00C (ARGX241220C210000) Stock Options, News & Quotes

172.00
0.000.00%

15min DelayTrading Jan 19 14:43 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Money Thrill

Nov 12 03:38

European Morning news [MarketDevil]

$argenx SE (ARGX.US)$ (ABM FN) China's regulator has approved the Supplemental Biologics License Application for Vyvgart Hytrulo for the treatment of adults suffering from CIDP. The biotech company announced this after the close.
This approval followed the Adhere study.This concerns an injection of 1,000 milligrams that can be administered once a week. About 50,000 people in China suffer from CIDP.
“It is the first and only treatment approved in China for CIDP,”...

Money Thrill

Nov 2 14:19

European News from journal HLN (LeatestNewsJournal)

$argenx SE (ARGX.US)$ Last quarter, the company recorded a net profit of 91.4 million euros, compared to a net loss of 72.6 million euros in the same period last year. After nine months there is a net profit of 58.9 million euros against a net loss of 195.9 million euros.
The difference between the operational results and the net result is mainly made up of the financial results and the taxes on the result. At the end of September, Argenx still h...

Meltyy

Jun 25 07:02

🔔 FDA PDUFA Update…

🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co (MRK.US)$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma (VRNA.US)$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab (GMAB.US)$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co (MRK.US)$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...

Meltyy

Jun 21 01:51

👀 Keep an eye out for the remaining PDUFAs in June! 🔥

$Sarepta Therapeutics (SRPT.US)$ : ELEVIDYS
$Harmony Biosciences (HRMY.US)$ : WAKIX (pitolisant)
$Bristol-Myers Squibb (BMY.US)$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE (ARGX.US)$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co (MRK.US)$ : Patritumab deruxtecan
$Verona Pharma (VRNA.US)$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals (RCKT.US)$ : KRESLADI (Marnetegragene autotemcel)

Meltyy

Jun 7 03:39

🚨 June PDUFAs

» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Eli Lilly and Co (LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron (GERN.US)$ : Imetelstat
$Merck & Co (MRK.US)$ : V116
$Amgen (AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics (SRPT.US)$ : ELEVIDYS
$Merck & Co (MRK.US)$ : KEYTRUDA ...